What is neotherma oncology?
We are answering the world's call for more effective, more humane cancer treatment. NeoTherma Oncology is developing a groundbreaking type of radio frequency (RF) thermal treament for deep, solid tumors that is expected to increase the effectiveness of current cancer treatments, while minimizing the harshest effects of chemotherapy and radiation.
How to invest in oncology stocks?
Choose an order type. Invest in the oncology stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price.
What is the price of Mersana Therapeutics stock today?
Mersana Therapeutics stock opened the day at $12.90 after a previous close of $12.85. The latest price was $12.88 (25-minute delay). Mersana Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$43,000 and employs 110 staff.
What is a neotherma oncology?
NeoTherma Oncology is developing VectRx™, a noninvasive thermal oncology therapeutic device system for treatment of a wide range of cancers in addition to Pancreatic Ductal Adenocarcinoma, the eighth most common cancer but the fourth leading cause of cancer death in the United States.
Who is the founder of Neotherma?
The inspiration for NeoTherma Oncology evolved from an idea developed by a broadcast engineer from Erie, Pennsylvania, John Kanzius, who early in his career learned about the power of radio waves from Erie, Pennsylvania, John Kanzius, who who was determined to find a better way to treat cancer... Read More
When did the Kanzius Foundation announce their lead researchers had determined they had sufficient preclinical data for the owners of
In 2014 the Kanzius Foundation announced that their lead researchers had determined they had sufficient preclinical data for the owners of the intellectual properties to summit a request to the FDA to move toward human trials.
How many people died from pancreatic cancer in 2017?
Pancreatic cancer is the fourth leading cause of cancer death in both men and women, with an estimated 43,090 deaths in 2017. Less than 20% of patients are candidates for surgery. Radiation therapy and chemotherapy are treatment options but rarely produce a cure.
How to invest in oncology stocks?
Invest in the oncology stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price. Buy the stock. Tap or click the Buy button on your brokerage account. Once you’ve invested in the cancer industry, track how your stock performs to decide when it’s time to sell.
What is Amgen stock?
discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. Amgen stock opened the day at $243.09 after a previous close of $244.28.
What is Five Prime Therapeutics?
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies . The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors.
What is the company that makes Revlimid?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
What is Cardiff Oncology?
Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops drugs for the treatment of cancer . Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin.
Can you turn a profit on oncology stocks?
While it’s possible to turn a profit investing in oncology stocks, keep in mind that — like any investment — oncology stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the cancer industry, so carefully vet your picks before you invest.
Oncology Pharma Expands on Feasibility Studies and Data
SAN FRANCISCO, CA / ACCESSWIRE / February 17, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc.
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc.
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
SAN FRANCISCO, CA / ACCESSWIRE / February 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc.
Oncology Pharma's New Year Update
SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc.
Oncology Pharma Meeting Towards Future Developments
SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc.
Oncology Pharma Year End Review and Outlook
SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc.
Oncology Pharma Research and Vision
SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc.
Nasdaq Global Select
ZIOPHARM Oncology Inc. is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies.
Environmental, Social, and Governance Rating
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Business Summary
ZIOPHARM Oncology Inc. is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies.
